Salbutamol sulfate
Sponsors
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A., Boehringer Ingelheim International GmbH, Boehringer Ingelheim RCV GmbH & Co. KG, Boehringer Ingelheim Espana S.A., Teva Branded Pharmaceutical Products R&D LLC
Conditions
AsthmaBronchiectasiscystic fibrosis bronchiectasis
Phase 2
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM)
RecruitingCTIS2023-503290-38-00
Start: 2023-09-05Target: 114Updated: 2026-01-21
A randomised, double-blind, placebo-controlled, parallel group trial evaluating safety, tolerability, pharmacodynamics and pharmacokinetics of BI 1291583 one tablet once daily over 12 weeks versus placebo in adult patients with cystic fibrosis bronchiectasis (ClairaflyTM)
CompletedCTIS2022-502835-21-00
Start: 2024-02-23End: 2024-10-03Target: 17Updated: 2024-12-17
Phase 3
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed--Dose Combination on Severe Asthma Exacerbations in Patients with Asthma
RecruitingCTIS2023-505435-12-00
Start: 2024-06-04Target: 770Updated: 2025-12-18
A 4-Week, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Fluticasone Propionate/Albuterol Sulfate Combination compared to Fluticasone Propionate, Albuterol Sulfate or Placebo delivered by Multidose Dry Powder Inhaler in Participants 12 Years and Older with Asthma
RecruitingCTIS2024-517991-39-00
Start: 2025-07-22Target: 555Updated: 2026-01-12